Chronic Cough – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Chronic Cough Market Outlook

Thelansis’s “Chronic Cough Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Cough treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Cough Overview

Cough is a natural defense mechanism that aids airway clearance by addressing secretions, exudates, or foreign bodies. The intricate nervous pathways, comprising afferent, central, and efferent components, play a key role in understanding the diverse mechanisms behind physiological and pathological cough, particularly chronic cough. Chronic cough, especially in adults, is a prevalent symptom necessitating medical attention, often lacking identifiable causes. In children, chronic cough differs in characteristics and is typically associated with identifiable underlying causes. For adults, chronic cough is defined as persisting for more than 8 weeks and is present in 5–10% of the adult population, predominantly among women over 50. These individuals often exhibit a hyper-reactive response to triggers, resulting in a pronounced tickling or irritation in the throat, compelling them to cough. Chronic cough can manifest irregularly, with some experiencing weeks of troublesome cough interspersed with asymptomatic days or weeks. Notably, 40% of adults with chronic cough undergoing specialist evaluation either have no identified cause (unexplained chronic cough) or continue to cough despite optimal treatment for conditions associated with chronic cough (refractory chronic cough). Various factors, such as respiratory infections, air pollutants, occupational irritants, allergens, eosinophils, refluxate, and biological traits like age or sex hormonal status, can sensitize and trigger cough, posing potential risk factors for chronic cough. Cigarette smokers are three times more likely to report chronic cough, primarily due to chronic bronchitis, although the majority of patients in cough specialist clinics are non-smokers. Managing chronic cough is often intricate, especially in patients with multiple comorbidities and when interventions may prove refractory. The approach involves treating underlying conditions contributing to chronic cough and implementing therapies targeting cough hypersensitivity in refractory or unexplained cough cases.

• Chronic cough affects approximately 10% of adults in various general populations.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: